Aortic histology and immunohistochemistry quantification

AF Alex J. Freemerman
LZ Liyang Zhao
AP Ajeeth K. Pingili
BT Bin Teng
AC Alyssa J. Cozzo
AF Ashley M. Fuller
AJ Amy R. Johnson
JM J. Justin Milner
ML Maili F. Lim
JG Joseph A. Galanko
MB Melinda A. Beck
JB James E. Bear
JR Jeremy D. Rotty
LB Lavanya Bezavada
HS Heather S. Smallwood
MP Michelle A. Puchowicz
JL Juan Liu
JL Jason W. Locasale
DL Douglas P. Lee
BB Brian J. Bennett
EA E. Dale Abel
JR Jeff C. Rathmell
LM Liza Makowski
request Request a Protocol
ask Ask a question
Favorite

Mice dissections were done as previously described (42). Briefly, following dissection, hearts were either transferred to 70% ethanol and stored at 4°C for future creation of formalin-fixed, paraffin-embedded sections or transferred to 30% sterile sucrose for 72 h for generating cryosectioning slides. Formalin-fixed, paraffin-embedded sections were stained with Masson’s trichrome for quantification of collagen content, necrotic core areas, and subendothelium cell numbers, and with anti-MOMA2 for MΦs. Frozen sections were stained with Oil Red O (ORO) for quantification of lesion area. A color deconvolution algorithm, developed by UNC Translational Pathology Laboratory, was used for digital quantification of collagen, reported as OD × percent of total positive area stained with collagen (4446). Necrotic core size and subendothelial cell nuclei were quantified on Masson’s trichrome–stained slides, which were normalized to the total quantified area. Necrotic core size was measured using Aperio ePathology software (Aperio, Buffalo Grove, IL), and subendothelial cell numbers were assessed manually by counting nuclei. Quantification of MΦs was calculated as OD × percent of total positive area stained with anti-MOMA2. Quantification of atherosclerotic lesions was done as described with modification (47, 48).

Do you have any questions about this protocol?

Post your question to gather feedback from the community. We will also invite the authors of this article to respond.

post Post a Question
0 Q&A